| 영문 | thrombin | 한글 | 트롬빈 |
|---|---|---|---|
| 설명 | 프로트롬빈에서 유래되는 효소로서, 섬유소원을 섬유소으로 변환시켜 혈액응고를 완성시킨다. |
||
| 영문 | anti-inflammatory agent | 한글 | 항염증제, 소염제, 염증약 |
|---|---|---|---|
| 설명 | 국소에 작용하여 염증을 치료하고 방지하는 약. 염증을 가라앉히는 약을 말한다. 조직을 긴축-치밀하게 하여 장액과 점액의 분비를 줄이고, 표면에 있는 작은 혈관에 빈혈을 일으켜 충혈되는 것을 방지함으로써 염증적 병변을 제거하여 모든 증세를 없앤다. 대부분의 수렴제-완화제-진양제가 이에 속한다. 중요한 성분으로는 알루미늄-비스무트-아연-납화합물(병반-페르마톨-아연화-연당 등) 등이 있다. 작용에 따라 항염증진통제와 항염증효소제로 나뉜다. |
||
| 영문 | anti-diuretic hormone; ADH | 한글 | 항이뇨호르몬 |
|---|---|---|---|
| 설명 | 뇌의 바닥에 붙어있는 호르몬을 주로 분비하는 작은 기관인 뇌하수체 후엽에서 분비되는 호르몬으로 콩팥에서 수분의 흡수를 촉진하여 체내에 수분의 양을 늘이는 역할을 한다. 동시에 혈관을 수축시키는 작용이 있어 혈압을 상승시키는 역할도 한다. ![]() ![]() ![]() |
||
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
|---|---|
| JVP | [POMD P 49 - 52] 1) Jugular Vein Pressure 2) Jugular Venous Pulse ... |
| AT III | angiotensin III; antithrombin III |
| ML | I, II, III, IV mucolipidosis I, II, III, IV |
| AB, Ab | 1) Anti-body; 항체 2) Anti-Biotics; 항생제 |
| AT III | Anti-thrombin III |
|---|---|
| TAT | Thrombin antithrombin III complex |
| TAT | Thrombin-Antithrombin III |
| A III | Angiotensin III |
| ANG III | Angiotensin III |
pseudounipolar bipolar III disorder
transverse facial vein
| receptors, thrombin | Cell surface proteins that specifically bind thrombin and trigger changes in the behaviour of blood cells. There are at least two types of thrombin receptors on platelets. The higher affinity receptors mediate the inhibition of stimulated adenylate cyclase, the secretion of acid hydrolases, and the activation of phospholipase a2. The lower affinity receptors are linked to phospholipase c and trigger platelet aggregation and exposure of fibrinogen binding sites. A human platelet thrombin receptor has been cloned and is a member of the family of peptide receptors. There are also thrombin receptors on endothelial cells and smooth muscle cells. (12 Dec 1998) |
|---|---|
| human thrombin | Thrombin obtained from human plasma by precipitation with suitable salts and organic solvents; same uses as thrombin. (05 Mar 2000) |
| thrombin | <enzyme> Protease (34 kD) generated in blood clotting that acts on fibrinogen to produce fibrin. Consists of two chains, A and B, linked by a disulphide bond. B chain has sequence homology with pancreatic serine proteases: cleaves at Arg Gly. Thrombin is produced from prothrombin by the action either of the extrinsic system (tissue factor + phospholipid) or, more importantly, the intrinsic system (contact of blood with a foreign surface or connective tissue). Both extrinsic and intrinsic systems activate plasma factor X to form factor Xa which then, in conjunction with phospholipid (tissue derived or platelet factor 3) and factor V, catalyses the conversion. (18 Nov 1997) |
| thrombin time | Test of the conversion of fibrinogen to fibrin by thrombin in which clotting time of plasma mixed with a thrombin solution is measured. Time is prolonged by afibrinogenaemia, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, heparin. Reptilase, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin. (12 Dec 1998) |
| agent, anti-infective | Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. (12 Dec 1998) |
| anti- | <prefix> A prefix meaning against, opposite or opposed to, contrary, or in place of, in relation to symptoms and diseases, curative. Often used in composition in many English words. It is often shortened to ant-; as, antacid, antarctic. Origin: Gr. against, opposite, instead of. Source: Websters Dictionary (20 Jun 2000) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
| anti-asthmatic agents | Drugs that are used to treat asthma. (12 Dec 1998) |
| anti-basement membrane antibody | Autoantibodies to renal glomerular basement membrane antigens. (05 Mar 2000) |
| anti-basement membrane glomerulonephritis | Glomerulonephritis resulting from anti-basement membrane antibodies, characterised by smooth linear deposits of IgG and C3 along glomerular capillary walls; includes rapidly progressive glomerulonephritis and glomerulonephritis in Goodpasture's syndrome. (05 Mar 2000) |
| anti-basement membrane nephritis | Glomerulonephritis produced by autologous or heterologous antibodies to the glomerular capillary basement membranes, the latter known as anti-kidney serum nephritis. (05 Mar 2000) |
| anti-black-tongue factor | A precursor of NAD, that is a product of the oxidation of nicotine. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
안티트롬빈Ⅲ주500IU - 새창
|
녹십자 |
A35504531 | Antithrombin III, human | 전문의약품 | 급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|